Astellas Pharma, Inc. has entered into a license agreement with MorphoSys AG for the use of its HuCAL technology. Under the terms of the agreement, Astellas will have access to the HuCAL GOLD antibody library for use in its internal drug discovery programs. MorphoSys will receive an upfront payment and annual user fees for the duration of the agreement. During the term of the agreement, Astellas will have access to the HuCAL GOLD library at its research site in Tsukuba, Japan and has the op...